← All trials
NCT04281498
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2020
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- Feb 24, 2020
- Last posted
- Feb 24, 2020
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- IncyteCollaborator
- CelgeneCollaborator
- National Institutes of Health (NIH)Collaborator
- National Cancer Institute (NCI)Collaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiSponsor investigator
- Icahn School of Medicine at Mount SinaiStudy chair
- University of Texas, San AntonioStudy chair
- Myeloproliferative Neoplasms Research ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.